Radioiodine Refractory Differentiated Thyroid Cancer Clinical Trials
2 recruiting trials for Radioiodine Refractory Differentiated Thyroid Cancer. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Radioiodine Refractory Differentiated Thyroid Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Early Phase 1 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Peking Union Medical College Hospital (1), Zhejiang Provincial People's Hospital (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is 177Lu-LNC1004 Injection (drug, 1 trial), followed by Sacituzumab Tirumotecan (SKB264) plus Tislelizumab, Sacituzumab Tirumotecan (SKB264).
Track Radioiodine Refractory Differentiated Thyroid Cancer trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer
177Lu-LNC1004 Injection, a radiopharmaceutical targeting FAP, has demonstrated preliminary antitumor effect in advanced FAP-positive solid tumor patients. The primary purpose of...
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
This is a multicenter, open-label, multi-cohort Phase II exploratory study designed to evaluate the efficacy and safety of sacituzumab tirumotecan with or without tislelizumab in...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Radioiodine Refractory Differentiated Thyroid Cancer, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Radioiodine Refractory Differentiated Thyroid Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Radioiodine Refractory Differentiated Thyroid Cancer, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.